par Villanueva, C.;Awada, Ahmad ;Campone, Mario;Machiels, Jean Pascal;Besse-Hammer, Tatiana;Magherini, E;Dubin, F;Semiond, D;Pivot, X
Référence European journal of cancer, 47, 7, page (1037-1045)
Publication Publié, 2011-05
Référence European journal of cancer, 47, 7, page (1037-1045)
Publication Publié, 2011-05
Article révisé par les pairs
Résumé : | Most patients with metastatic breast cancer (MBC) progress after chemotherapy. Cabazitaxel (XRP6258) is a new taxoid that is active in chemotherapy-resistant tumour cell lines. The objectives of this phase I/II study were to assess the maximum tolerated dose (MTD), safety profile, pharmacokinetics, and activity of cabazitaxel plus capecitabine in patients with MBC who had been previously treated with taxanes and anthracyclines. |